Research programme: malonyl coenzyme A decarboxylase inhibitors - ChugaiAlternative Names: CBM-300864; CBM-301940
Latest Information Update: 31 Jan 2007
At a glance
- Originator Chugai Pharmaceutical
- Mechanism of Action Malonyl CoA decarboxylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Coronary disorders
Most Recent Events
- 01 Jul 2006 This programme is still in active development